|Articles|April 18, 2018

FDA OKs Burosumab for Rare Form of Rickets

The serious condition leaves children with bowed legs, short stature, and bone and dental pain.

The US FDA this week approved burosumab (Crysvita, Ultragenyx) as the first treatment for x-linked hypophosphatemia (XLH) in adults and children ages 1 and older.

The serious condition leaves children with bowed legs, short stature, and bone and dental pain. Adults with XLH may experience joint pain, impaired mobility, tooth abscesses, and hearing loss. Adults with XLH are also at greater risk of bone fractures. In the United States, XLH affects an estimated 3000 children and 12,000 adults.

This article originally appeared on MDmag.com.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME

Panel Discussion Registration

The Educated Pharmacist - Weighing In: Translating Evidence to Practice — A Multidisciplinary Analysis of Obesity Pharmacotherapy Implementation and Team-Based Care

Thursday, August 27, 2026 | 1:00 PM – 2:30 PM EDT

Online Article

Paroxysmal Nocturnal Hemoglobinuria: Managed Care Strategies to Mitigate Burden and Enhance Outcomes

2.0 Credits / Immunology, Rare Diseases, Hematology

FDA OKs Burosumab for Rare Form of Rickets

Related Content

Clinical Forum Events Highlight the Evolving Landscape of Obesity Management

Antibody-Drug Conjugates and HER2 Guidelines Are Reshaping Breast Cancer Treatment

Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types

Study: Early Nephrology Consultation Triggered by AI Fails to Prevent Acute Kidney Injury

FDA Accepts NDA for AD109 to Treat of Adults With Obstructive Sleep Apnea

Latest CME

The Educated Pharmacist - Weighing In: Translating Evidence to Practice — A Multidisciplinary Analysis of Obesity Pharmacotherapy Implementation and Team-Based Care

Paroxysmal Nocturnal Hemoglobinuria: Managed Care Strategies to Mitigate Burden and Enhance Outcomes

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

NEIAP Conference 2026

NEIAP 2026 Annual Forum

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

The Pharmacist's Role in Palliative and End of Life Symptom Management

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

Reducing the Treatment Burden in HIV Management: The Pharmacist’s Role in Long-Acting Injectable Adoption

Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

From Guidelines to Action: Implementing Pneumococcal Vaccine ACIP Recommendations in Long-Term Care Settings

Effective Strategies to Manage Hyperglycemia When Treating with PI3K and AKT Inhibitors

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

New Horizons in ATTR-CM: Therapeutic Advances and Strategic Insights

Innovations in Retinal Therapies: A Managed Care Perspective on Anti-VEGF Advancements

Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Multidisciplinary Insights to Enhance Biomarker Testing Practices in Non-Small Cell Lung Cancer

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia With Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

New Therapeutic Targets in the Treatment of Generalized Myasthenia Gravis: Understanding Disease Pathways and Pharmacist-Led Strategies for Optimized Care

Minimizing Injection Burden: Anti-VEGF Innovation for Retinal Disease Management

Beyond the Nasal Passage: Managing Chronic Rhinosinusitis With Nasal Polyps With Biologics and Pharmacist-Led Approaches

Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Managing Overactive Bladder in Older Adults: Challenges and Strategies for Long-Term Care

Bridging Clinical and Access Gaps in Phenylketonuria: A Managed Care Perspective

Advancing the Idiopathic Pulmonary Fibrosis Treatment Landscape: What’s Next in Care

Managing Steroid-Refractory Chronic Graft-versus-Host Disease With Novel Therapies: Opportunities for Pharmacist-Led Interventions

Enhancing The Role of Oncology Pharmacists in Multidisciplinary Myeloproliferative Neoplasm Care

HER2-Positive Metastatic Breast Cancer: A Managed Care Perspective on Emerging Therapies and Clinical Data

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

Collaborative Practice Agreement Implementation and Adherence: A Practical Roadmap for Oncology Pharmacists

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Advancing Patient Safety: Strategies to Address Safety Risks and Adherence Barriers to Optimize Outcomes for Patients on Injectable Therapies

An American Journal of Managed Care Forum: Bridging Evidence and Access in Advanced Small Cell Lung Cancer

The Educated Pharmacist: Overcoming Clinical Inertia—An Interactive Case Workshop for Optimizing Insulin Use

Advancing Chronic Kidney Disease Detection and Cardiovascular Risk Reduction in Complex Patients

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations (Pharmacy Technician Credit)

Continuing the Conversation: Pharmacist Interventions to Optimize T2D Care and Break Through Clinical Inertia

Hat Trick for Hypertension: Strategies to Improve Outcomes With Single-Pill Combinations

Bridging Knowledge Gaps in HR+/HER2– Early-Stage Breast Cancer

Optimizing HER2-Directed Therapy in Metastatic Breast Cancer: From HER2-Positive to HER2-Ultralow

Shaping the Future of Generalized Myasthenia Gravis Management: A Focus on Novel Treatment Approaches

Expert Insights on the Horizon of HER2-Directed Therapy

Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

Chronic Obstructive Pulmonary Disease and Inflammation: Practical Approaches to Integrating Biologic Therapy

Understanding Type 2 Inflammation and Its Role Across Various Immune-Related Diseases

Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Addressing the Burden of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: The Pharmacist's Contribution to Patient Care

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

Shifting Perspectives in Treatment-Resistant Depression: Novel Therapies and Patient-Centered Care

Navigating Adverse Effects in HR+/HER2-Negative Metastatic Breast Cancer: Tailored Management Plans and Pharmacist Interventions for Improved Outcomes

Updated Guidance and Managed Care Strategies to Optimize Care in EGFR Mutated NSCLC